<DOC>
	<DOCNO>NCT01886898</DOCNO>
	<brief_summary>The primary objective trial ass growth infant enrol study . Other parameter measure include microbiota balance certain blood biochemical value . In addition infant ' digestive tolerance formulae frequency morbidity investigate .</brief_summary>
	<brief_title>Synbiotics Growth</brief_title>
	<detailed_description>The infant recruit birth 14 day life start allocate study formula soon enrol . In practice tend immediately birth . The treatment period , term data necessary primary outcome , reach 16 week old . Growth measurement collect five separate occasion period , ie 2 , 4 , 8 , 12 16 week life . Although study intervention formally end 16 week , useful follow visit 26 week collect data gut microflora sub-group infant already provide stool sample 8 week . This follow-up visit benefit subject receive weight check clinical examination paediatrician offer subject ( invasive procedure carry ) .</detailed_description>
	<criteria>Healthy newborn infant Infant less14 day old day enrollment Birthweight 2500g 4500g Gestational age 37 week Singleton birth Infant 's mother , 14th day child 's life , elect breastfeed Infant randomize treatment group expect exclusively feed formula enrolment 16 week old Having obtain his/her legal representative 's informed consent Currently participate another clinical trial Congenital illness malformation may affect normal growth Significant prenatal and/or postnatal disease Rehospitalisation 2 day first 14 day life . ( Exceptionally , infant rehospitalized jaundice may enrol study ) . Receiving antibiotic treatment time enrolment 5 previous day . Receiving infant formula contain probiotic and/or prebiotics time enrolment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>